Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine prophylaxis for COVID-19 prevention in nursing home residents and staff
2020-002287-31Phase 3Active
- Sponsor
- Fundación IMABIS
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydroxychloroquine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Fundación IMABIS. Primary endpoints: Incidence of secondary SARS-CoV-2 infection, Mortality and 4 more. Started May 2020; status: active.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002287-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002287-31.